Primary source: Download PDF
The FDA has introduced new requirements for the verification and validation of Digital Health Technologies used to generate Digitally Derived Measures (DDMs) in clinical investigations.
These guidelines standardize the collection of safety and efficacy data, facilitating continuous and real-time monitoring of adverse events, and improving the reliability of clinical outcomes derived from DHTs.
Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Framework for using digital health technologies (DHTs) to capture clinical outcomes; emphasis on clinical relevance and evidence requirements.
Standardizes the use of digital tools for safety and efficacy endpoint collection in clinical trials. This facilitates continuous and real-time monitoring of adverse events and improves the reliability of safety data captured via DHTs.
May require updates to regulatory submissions and oversight due to new DDM definitions.
Need to incorporate DDMs into compliance frameworks for medical devices.
Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.
The FDA's joint paper emphasizes the importance of digitally derived measures (DDMs) in clinical investigations, ensuring they are evidence-based and fit for purpose. Key aspects include verification and validation requirements of DHTs and a focus on the meaningfulness of outcomes to patients, which influences safe and effective medical product development.
What changed: The FDA has introduced new requirements for the verification and validation of Digital Health Technologies used to generate Digitally Derived Measures (DDMs) in clinical investigations.
Why it matters: These guidelines standardize the collection of safety and efficacy data, facilitating continuous and real-time monitoring of adverse events, and improving the reliability of clinical outcomes derived from DHTs.
Practical implication: Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
